5570-78-5

Usage

Uses

Used in Pharmaceutical Synthesis:
1-isopropylpiperidin-4-ol is used as a key intermediate in the synthesis of various pharmaceuticals for its unique structural properties that can be leveraged to create new drug molecules.
Used in Medicinal Chemistry:
1-isopropylpiperidin-4-ol is used as a potential drug candidate in medicinal chemistry due to its structural features that may confer biological activity, warranting further exploration into its therapeutic potential.
Used in Drug Design:
1-isopropylpiperidin-4-ol is utilized in drug design for its ability to contribute to the development of novel compounds with specific pharmacological properties, capitalizing on its hydrophobic and hydrophilic balance provided by the isopropyl and alcohol groups, respectively.

InChI:InChI=1/C8H17NO/c1-7(2)9-5-3-8(10)4-6-9/h7-8,10H,3-6H2,1-2H3

Upstream product

• 5355-68-0 1-Isopropyl-4-piperidone 
• 16217-23-5 3,3'-isopropylimino-di-propionic acid diethyl ester 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 67-64-1 acetone 
• 75-26-3 isopropyl bromide 

Downstream Products

• 397275-42-2 4-[(1-isopropyl-4-piperidinyl)oxy]benzonitrile 
• 1048954-89-7 C₂₅H₃₄N₂O₂ 
• 1260098-12-1 1-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-2-morpholin-4-yl-ethanone 
• 916344-70-2 1-isopropyl-4-(4-nitrophenoxy)piperidine 

Relevant academic research and scientific papers

Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity

A series of chemical optimizations guided by in vitro affinity at a histamine H3 receptor (H3R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake-promoting effects with decreased rapid-eye-movement sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety studies in animals have been successfully completed without any concern for further development.

NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS

The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS

The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS

The invention relates to compounds of formula (I), wherein X1a, X1 to X5, Ra, Rb, n and R have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

NPY ANTAGONISTS, PREPARATION AND USES

The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

TETRAHYDRONAPHTHYRIDINE DERIVATIVE

The invention relates to 6-[2-(1-Isopropyl-piperidin-4-yloxy)-7,8-dihydro-5H-[1 ,6]naphthyridin-6-yl]-nicotinamide of Formula (I) and to processes for the preparation of, compositions containing and the uses of, the compound. The compound is an H3 ligand and is useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

1,1-DIOXO-THIOMORPHOLINYL INDOLYL METHANONE DERIVATIVES

The present invention relates to compounds of formula I wherein R1, R2 and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

1,5-Substituted indol-2-yl amide derivatives

The present invention relates to compounds of formula I wherein R1 to R4 and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

3- Or 4-monosubstituted phenol derivatives useful as H3 ligands

The invention relates to 3- or 4-monosubstituted phenol derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands

The invention relates to tetrahydronaphthyridine derivatives having formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said tetrahydronaphthyridine derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.